Should You Invest in Vanguard S&P 500 ETF Like Warren Buffett and Ken Griffin?by Mark Eisenberg 24.04.2024Billionaires Warren Buffett and Ken Griffin own Vanguard's S&P 500 ETF. Despite contradictory strategies, investing in this popular ETF has ...
Micron to Receive $6.1 Billion for Semiconductor Plantsby Mark Eisenberg 21.04.2024Micron's plans of expanding its manufacturing footprint in the US adds to the recent awards granted to chipmakers, aiming to ...
Boeing Whistleblower Reveals Criminal Coverupby Mark Eisenberg 20.04.2024The Justice Department and FBI are conducting a criminal probe into the 2019 Alaska Airlines flight incident. Boeing stands by ...
Tesla remains committed to 1,800-mile charging corridor for semi trucksby Lilu Anderson 20.04.2024The Tesla Semi program faces challenges and delays, but is still attracting customers. Funding hydrogen stations is considered a waste.
Stocks Drop Amid Fears of Delayed Rate Cutsby Terry Bingman 08.04.2024Rising crude oil prices could add to inflation concerns. US and China manufacturing figures were positive, but S&P 500 had ...
Crypto Carnage: Bitcoin, Ethereum, Bonk Plummet – Where to Now?by John Darbie 07.04.2024The market is turning against investors as ETFs fail to provide a catalyst for crypto values. With fundamentals driving the ...
March Jobs Report: Will Momentum Continue in New Quarter?by Terry Bingman 01.04.2024Stocks closed out a strong first quarter, but this week's jobs report will determine if momentum continues. Other indicators suggest ...
The AI Nightmare: Will It Serve Humans Too Well?by Lilu Anderson 01.04.2024The age of AI has begun, bringing new anxieties. Efforts are being made to ensure AI only does what humans ...
Rocky Mountain Chocolate Factory: Financial Report Analysisby Mark Eisenberg 01.04.2024Discover the financial challenges Rocky Mountain Chocolate Factory faces through a detailed report on profitability and cash flow issues. Read ...
ChenGuang Biotech Group: Strong Financials Despite Weakness?by Mark Eisenberg 30.03.2024ChenGuang Biotech Group's share price has dropped 7.5% in the past three months. However, their ROE of 14% shows a ...